NASDAQ:NAUT Nautilus Biotechnology (NAUT) Stock Price, News & Analysis $2.06 -0.10 (-4.40%) As of 12:52 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Nautilus Biotechnology Stock (NASDAQ:NAUT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nautilus Biotechnology alerts:Sign Up Key Stats Today's Range$1.88▼$2.1550-Day Range$0.85▼$2.2552-Week Range$0.84▼$4.31Volume5.37 million shsAverage Volume1.42 million shsMarket Capitalization$262.77 millionP/E RatioN/ADividend YieldN/APrice Target$3.83Consensus RatingModerate Buy Company Overview Nautilus Biotechnology, Inc. is a life sciences technology company developing tools for large-scale protein analysis. Its goal is to enable more comprehensive, sensitive and efficient study of the proteome, the full set of proteins expressed by a biological system, to support research in drug discovery, disease biology and translational science. The company's primary offering is the Nautilus Proteome Analysis Platform, which combines a proprietary analytical instrument, consumables and software. The platform is designed to identify and quantify large numbers of proteins from biological samples and provide researchers with data that may help characterize disease mechanisms, evaluate therapeutic targets and assess drug responses. Nautilus Biotechnology was founded in 2016 and is headquartered in Seattle, Washington. The company became publicly traded in 2021 through a business combination with Arya Sciences Acquisition Corp III. Co-founder Sujal Patel serves as chief executive officer, while co-founder Parag Mallick serves as chief scientific officer. Its technology is intended for use by pharmaceutical, biotechnology, academic and other life sciences researchers.AI Generated. May Contain Errors. Read More Nautilus Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreNAUT MarketRank™: 3.050825255435 of 5 starsNautilus Biotechnology scored higher than 61% of companies evaluated by MarketBeat, and ranked 422nd out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingNautilus Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNautilus Biotechnology has a consensus price target of $3.83, representing about 85.6% upside from its current price of $2.07.Amount of Analyst CoverageNautilus Biotechnology has only been the subject of 4 research reports in the past 90 days.Read more about Nautilus Biotechnology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nautilus Biotechnology are expected to decrease in the coming year, from ($0.52) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nautilus Biotechnology is -4.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nautilus Biotechnology is -4.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNautilus Biotechnology has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nautilus Biotechnology's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.70% of the float of Nautilus Biotechnology has been sold short.Short Interest Ratio / Days to CoverNautilus Biotechnology has a short interest ratio ("days to cover") of 1.42, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nautilus Biotechnology has recently increased by 41.38%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNautilus Biotechnology does not currently pay a dividend.Dividend GrowthNautilus Biotechnology does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.91 News SentimentNautilus Biotechnology has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Nautilus Biotechnology this week, compared to 1 article on an average week.Search Interest11 people have searched for NAUT on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Nautilus Biotechnology to their MarketBeat watchlist in the last 30 days. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nautilus Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders41.10% of the stock of Nautilus Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.71% of the stock of Nautilus Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nautilus Biotechnology's insider trading history. Receive NAUT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NAUT Stock News HeadlinesNautilus Biotechnology to Report Third Quarter 2026 Financial Results on October 274 hours ago | quiverquant.comQNautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 20264 hours ago | globenewswire.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 15 at 1:00 AM | Investors Alley (Ad)Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock Has Consensus Price Target of $3.83 According to AnalystsOctober 7, 2026 | americanbankingnews.comStock Traders Buy High Volume of Call Options on Nautilus Biotechnology (NASDAQ:NAUT)October 5, 2026 | americanbankingnews.comVoyager Will Take Center Stage In Nautilus' Commercial PushOctober 1, 2026 | seekingalpha.comRoth Capital initiates coverage of Nautilus Biotechnology with buySeptember 29, 2026 | msn.comNautilus Biotechnology Analyst Price TargetsSeptember 10, 2026 | benzinga.comSee More Headlines NAUT Stock Analysis - Frequently Asked Questions How have NAUT shares performed this year? Nautilus Biotechnology's stock was trading at $1.95 at the beginning of the year. Since then, NAUT stock has increased by 5.9% and is now trading at $2.0650. How were Nautilus Biotechnology's earnings last quarter? Nautilus Biotechnology, Inc. (NASDAQ:NAUT) released its quarterly earnings data on Monday, July, 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03. The company had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.10 million. Read the conference call transcript. How do I buy shares of Nautilus Biotechnology? Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nautilus Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nautilus Biotechnology investors own include Illumina (ILMN), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Amgen (AMGN), ASML (ASML), Broadcom (AVGO) and DraftKings (DKNG). Company Calendar Last Earnings7/27/2026Today10/15/2026Next Earnings (Estimated)10/26/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, NAUT's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:NAUT CIK1808805 Webwww.nautilus.bio Phone206-333-2001FaxN/AEmployees130Year Founded2016Price Target and Rating Average Price Target for Nautilus Biotechnology$3.83 High Price Target$4.00 Low Price Target$3.50 Potential Upside/Downside+83.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59 million Net MarginsN/A Pretax Margin-29,747.89% Return on Equity-37.58% Return on Assets-30.83% Debt Debt-to-Equity RatioN/A Current Ratio10.14 Quick Ratio10.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.24 per share Price / Book1.68Miscellaneous Outstanding Shares127,250,000Free Float74,953,000Market Cap$265.32 million OptionableOptionable Beta0.73 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:NAUT) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nautilus Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nautilus Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
